^
Association details:
| Biomarker: | DOT1L mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer
Published date:
08/08/2023
Excerpt:
We characterized the frequency and genomic characteristics of DOT1L mutations in a cohort of 393 treatment-naïve stage III/IV NSCLC patients using targeted next-generation sequencing....The median progression-free survival of DOT1L-mutated patients receiving ICIs was significantly longer than that of DOT1L-wildtype patients on ICIs (21.1 vs. 3.9 months, P=0.006).